Study of Children With Cystic Fibrosis in South Brittany to Identify Biomarkers Predicting Lung Infection Risk

What this Trial Is About

Researchers are investigating the use of Porphyromonas as a biomarker to predict the risk of initial colonization by Pseudomonas aeruginosa in children aged 0 to 18 years who have cystic fibrosis. This study is descriptive and monocentric, aiming to identify and validate biomarkers that may predict clinical evolution in these patients. The study consists of three phases pre-inclusion at the first visit to the Cystic Fibrosis Reference Center CRCM, inclusion between the second visit around 2 months old and six months of age, and follow-up until the child reaches 36 months old. During the study, clinical and paraclinical data along with biological samples such as bronchial secretions, blood, stools, superficial skin, dental plaque, and urine will be collected. Dermatological and dental follow-ups are scheduled annually at a regional hospital. Participants will attend visits based on the usual care schedule for cystic fibrosis infants. Respiratory tests and sample collections will be performed during these visits at the CRCM. The primary outcome measured is the presence of Pseudomonas aeruginosa in bronchial secretions over the three-year period. The study includes monitoring through clinical exams and biological testing to track the development and colonization status of the children.

Patienthèque of Finisterian (South of Brittany) Children With Cystic Fibrosis in the Time of Precision Medicine